Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 8/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.45 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14375469 | 0.86 | HRH3 (0.51) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4931385 | 0.82 | L3MBTL3 (0.68) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL20031286 | 0.81 | HRH3 (0.54) | HRH3L3MBTL1LSSGAA | |
| SCHEMBL4936788 | 0.81 | L3MBTL3 (0.66) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4937869 | 0.81 | L3MBTL3 (0.66) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4941296 | 0.81 | L3MBTL3 (0.66) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4931707 | 0.81 | L3MBTL3 (0.66) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4937880 | 0.81 | L3MBTL3 (0.66) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4938232 | 0.79 | PARP1 (0.43) | HRH3GAA | |
| SCHEMBL12073571 | 0.79 | CHRM5 (0.48) | L3MBTL3L3MBTL1MBTD1TP53BP1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556046-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | claimed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | claimed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| EP-1556046-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | HRH2, HNMT, HRH3 | HRH3 3/4885L3MBTL3 4833/4885L3MBTL1 4814/4885 |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | HRH2, HNMT, HRH3 | HRH3 3/4885L3MBTL3 4833/4885L3MBTL1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.